There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DermTech (DMTK – Research Report) and NeuroPace (NPCE – Research Report) with bullish sentiments.
DermTech (DMTK)
Lake Street analyst Thomas Flaten maintained a Buy rating on DermTech today and set a price target of $6.00. The company’s shares closed last Thursday at $2.57, close to its 52-week low of $1.55.
According to TipRanks.com, Flaten is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for DermTech with a $6.00 average price target, a 167.9% upside from current levels. In a report released today, Craig-Hallum also assigned a Buy rating to the stock.
See the top stocks recommended by analysts >>
NeuroPace (NPCE)
Lake Street analyst Frank Takkinen reiterated a Buy rating on NeuroPace today and set a price target of $10.00. The company’s shares closed last Wednesday at $4.36.
According to TipRanks.com, Takkinen is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for NeuroPace with a $7.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DMTK:
